Recommendations for SARS-CoV-2/COVID-19 testing: A scoping review of current guidance by Arévalo Rodriguez, Ingrid et al.
1Arevalo- Rodriguez I, et al. BMJ Open 2021;11:e043004. doi:10.1136/bmjopen-2020-043004
Open access 
Recommendations for SARS- CoV-2/
COVID-19 testing: a scoping review of 
current guidance
Ingrid Arevalo- Rodriguez   ,1 Pamela Seron,2 Diana Buitrago- García,3 
Agustin Ciapponi,4 Alfonso Muriel   ,5 Paula Zambrano- Achig,6 Rosa del Campo,7 
Juan Carlos Galán- Montemayor,8 Daniel Simancas- Racines,6 
Jose A Perez- Molina,9 Khalid Saeed Khan,10 Javier Zamora   5,11
To cite: Arevalo- Rodriguez I, 
Seron P, Buitrago- García D, 
et al.  Recommendations 
for SARS- CoV-2/COVID-19 
testing: a scoping review of 
current guidance. BMJ Open 
2021;11:e043004. doi:10.1136/
bmjopen-2020-043004
 ► Prepublication history and 
additional material for this paper 
is available online. To view these 
files, please visit the journal 
online (http:// dx. doi. org/ 10. 
1136/ bmjopen- 2020- 043004).
Received 22 July 2020
Revised 15 October 2020
Accepted 22 December 2020
For numbered affiliations see 
end of article.
Correspondence to
Dr Javier Zamora;  
 j. zamora. 1@ bham. ac. uk
Original research
© Author(s) (or their 
employer(s)) 2021. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published by 
BMJ.
ABSTRACT
Background Testing used in screening, diagnosis and 
follow- up of COVID-19 has been a subject of debate. 
Several organisations have developed formal advice about 
testing for COVID-19 to assist in the control of the disease. 
We collated, delineated and appraised current worldwide 
recommendations about the role and applications of tests 
to control SARS- CoV-2/COVID-19.
Methods We searched for documents providing 
recommendations for COVID-19 testing in PubMed, 
EMBASE, LILACS, the Coronavirus Open Access Project 
living evidence database and relevant websites such as 
TRIP database, ECRI Guidelines Trust, the GIN database, 
from inception to 21 September 2020. Two reviewers 
applied the eligibility criteria to potentially relevant 
citations without language or geographical restrictions. 
We extracted data in duplicate, including assessment of 
methodological quality using the Appraisal of Guidelines 
for Research and Evaluation- II tool.
Results We included 47 relevant documents and 327 
recommendations about testing. Regarding the quality of 
the documents, we found that the domains with the lowest 
scores were ‘Editorial independence’ (Median=4%) and 
‘Applicability’ (Median=6%). Only six documents obtained 
at least 50% score for the ‘Rigour of development’ 
domain. An important number of recommendations 
focused on the diagnosis of suspected cases (48%) 
and deisolation measures (11%). The most frequently 
recommended test was the reverse transcription- PCR 
(RT- PCR) assay (87 recommendations) and the chest 
CT (38 recommendations). There were 22 areas of 
agreement among guidance developers, including the 
use of RT- PCR for SARS- Cov-2 confirmation, the limited 
role of bronchoscopy, the use chest CT and chest X- rays 
for grading severity and the co- assessment for other 
respiratory pathogens.
Conclusion This first scoping review of recommendations 
for COVID-19 testing showed many limitations in the 
methodological quality of included guidance documents 
that could affect the confidence of clinicians in their 
implementation. Future guidance documents should 
incorporate a minimum set of key methodological 
characteristics to enhance their applicability for decision 
making.
INTRODUCTION
COVID-19, a human respiratory disease 
pandemic caused by a new coronavirus 
(SARS- CoV-2) since March 2020, has been 
reported in 3 175 207 cases including 224 172 
deaths worldwide.1 2 Its peak quickly saturated 
the response capacity of healthcare organisa-
tions, even in high- performing systems, seri-
ously affecting medical provision.3 Effective 
infection control should rely on provision 
of tests. Initial strategies have focused on 
case identification and contact tracing, as in 
previous coronavirus epidemics,4–6 although 
testing on a massive scale has also been 
suggested as a key public health strategy.6–8 
Testing all patients with suspected infection 
is the ideal method for infection control, 
but several countries have limited testing 
capacity unrealistic, and a prioritising process 
is applied.3 9 10
Testing used in screening, diagnosis and 
follow- up of COVID-19 has been a subject 
of debate. Besides symptoms and signs, tests, 
Strengths and limitations of this study
 ► This scoping review focused on documents provid-
ing recommendations about COVID-19 testing, pro-
duced by global health agencies, scientific societies 
and government agencies worldwide.
 ► We applied the Appraisal of Guidelines for Research 
and Evaluation- II tool, to assess the quality of the 
documents providing recommendations about 
COVID-19 testing.
 ► We included the latest version of documents provid-
ing recommendations for adult populations, without 
language or publication status restrictions. Search is 
current up to 21 September 2020.
 ► We classified each recommendation according to its 
application, the index tests involved and the action 
recommended. We summarised the areas of agree-
ment among developers about COVID-19 testing.
2 Arevalo- Rodriguez I, et al. BMJ Open 2021;11:e043004. doi:10.1136/bmjopen-2020-043004
Open access 
such as nucleic acid amplification tests (NAATs), serology 
tests (including lgG and lgM) as well as imaging (chest 
CT, ultrasound and chest X- ray), have been considered 
for this condition.11–13 However, there are variations 
in the evidence evaluating the properties of COVID-19 
tests in different public health and clinical scenarios.14–16 
In a pandemic, there is a need for timely guidance to 
direct the testing of suspected, probable and confirmed 
COVID-19 cases. To efficiently use, available resources to 
control the spread of the disease, several organisations 
have developed formal advice about testing for COVID-
19.17–20 In this scoping review, we collated and catego-
rised guidance about the role and applications of tests 
for SARS- CoV-2/COVID-19, to provide an overview of 
the current recommended testing strategies, as well as 
their quality following the criteria of a standardised tool 
to assess documents providing clinical guidance. While 
other reviews have focused on guidance about COVID-19 
treatments21 22 or selected populations,23–25 this is the first 
scoping review summarising COVID-19 testing recom-
mendations along with a comprehensive assessment of 
the quality of their development.
METHODS
We searched for guidance documents about the use 
of tests in the diagnosis and management of adult 
COVID-19 patients, without language or publication 
status restrictions. A document or report was eligible if 
it was self- declared as a guideline, guidance or protocol 
(using keywords such as ‘practice guideline,’ ‘consensus,’ 
‘guidance’, ‘position statement’ and ‘guideline’), and if 
it provided explicit recommendations about COVID-19 
testing for adult healthier population. We included 
documents providing recommendations about the use 
of any test, including symptoms and signs of COVID-
19, laboratory- based molecular tests, serology tests and 
imaging, and presented as sentences or paragraphs. Guid-
ance documents exclusively focused on special popula-
tions (ie, patients with chronic obstructive pulmonary 
disease, critical care, pregnant women, cancer patients 
or children), specific settings (ie, workplaces, nursing 
homes), those developed for local use (ie, those devel-
oped by individual healthcare institutions), as well as 
other evidence synthesis documents no providing explicit 
recommendations (ie, rapid responses and rapid reviews) 
were excluded. A detailed structured question (Patients, 
Index Test, Outcome (PCO)) can be consulted in online 
supplemental appendix 1.
Data sources and searches
We searched guideline repositories and websites of 
government agencies, scientific societies and interna-
tional organisations related to COVID-19 management, 
such as WHO, the Centers for Disease Control and 
Prevention (CDC), as well as manual searching of 28 
websites (online supplemental appendix 2). In addition, 
we searched MEDLINE (Ovid SP, 1946 to 21 September 
2020), Embase (Ovid SP, 1982 to 21 September 2020) and 
LILACS (iAH English) (BIREME, 1982 to 21 September 
2020). We also search on the internet for documents from 
the 30 countries more affected by COVID-19 confirmed 
cases, as reported by WHO in the situation report #15326 
(online supplemental appendix 3). We did not apply any 
language or geographic restrictions. We used EndNote 
X9 software to create a database for the management of 
the search results.
Study selection and quality assessment
Two reviewers applied the eligibility criteria and extracted 
relevant data on main characteristics from potentially 
relevant documents, registering reasons for exclusion. 
An additional reviewer checked all the extracted infor-
mation for accuracy (non- independent verification). 
For the quality assessment of included documents, two 
reviewers independently rated each document using 
the Appraisal of Guidelines, Research and Evaluation 
(AGREE)- II tool.27 The AGREE- II tool is a validated tool 
for the assessment of the quality and reporting of prac-
tice guidelines.28–30 In particular, this tools helps to stake-
holders, clinicians and users in general in the evaluation 
of the quality of documents that are candidates for use in 
clinical practice, as well as those involved in policy- related 
decisions.27 This tool consisted of 23 key items organised 
in six domains: scope and purpose, stakeholder involve-
ment, the rigour of development, clarity of presentation, 
applicability, editorial independence and two overall 
evaluation items. Each item was graded using a scale of 7 
points: from 1, meaning ‘strongly disagree’, to 7, meaning 
‘strongly agree’. The total was presented as a percentage 
of the maximum possible score for that domain (from 
0% to 100%). For further analysis, we highlighted those 
recommendations belonging to documents with a score 
of ≥50% in domain 3 of the AGREE- II tool (‘Rigour of 
Development’), as indication of a sound methodology in 
their development. This domain involves questions about 
the use of systematic methods in search of evidence, the 
comprehensive evaluation of the strength and limitations 
of eligible studies, the methods for formulating the final 
recommendations and their external review by experts, 
among other issues.27 Discrepancies were resolved by a 
consensus.
Data extraction and data synthesis
For each eligible document, we extracted information 
about the country and region where the document was 
developed, the date of last update, the main institu-
tion developing the guidance, the methodologies to 
produce the guidance document and the recommenda-
tions, as well as the assessment of conflict of interest. All 
recommendations provided by the included guidance 
documents were extracted in an Excel spreadsheet. We 
classified each recommendation according to their appli-
cation, following the disease pathway suggested by Cheng 
et al31, as follow:
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 ► Incubation period with screening asymptomatic 
patients and monitoring contacts: Those recommen-
dations about the assessment of at- risk individuals 
without symptoms and their likelihood of a current 
SARS- Cov-2 infection, as well as those recommen-
dations about contact tracing and monitoring of 
contacts of suspected, possible and confirmed cases 
of COVID-19.
 ► Symptomatic illness with testing of symptomatic cases: 
Those recommendations about the triage of symp-
tomatic individuals with a reasonable likelihood of 
COVID-19.
 ► Symptomatic illness needing diagnosis: Those recom-
mendations about the confirmation of COVID-19 
disease in an individual infected with SARS- CoV-2 
after triage testing.
 ► Symptomatic illness exploring competitive diagnosis: 
Those recommendations about rule- out competing 
diagnosis (ie, influenza- like illness) of sympto-
matic individuals with a reasonable likelihood of a 
SARS- Cov-2 infection/ COVID-19.
 ► Symptomatic illness grading disease severity: Those 
recommendations about the classification of 
confirmed cases and the assessment of severity to 
treatment decisions.
 ► Symptomatic illness monitoring and treatment modi-
fication: Those recommendations about the follow- up 
of confirmed COVID-19 case for further treatment 
modifications.
 ► Convalescence or deisolation discharge: Those 
recommendations about the end of deisolation or the 
hospital discharge of institutionalised patients.
We extracted the test(s) covered by each recommen-
dation in a standardised format, as well as the direc-
tion of the recommendation (for/ against), and their 
strength (weak, strong), if available. We generated tables 
and figures summarising the role of tests during the 
COVID-19 testing, as well as the areas of consensus and 
recommendations supported by two or more documents. 
All descriptive analyses were performed in STATA V.16.0. 
We followed the Preferred Reporting Items for Systematic 
Reviews and Meta- Analyses for scoping reviews.32
Patient and public involvement
Patients were not involved in this research.
RESULTS
Electronic searches yielded 4648 citations from Medline, 
Embase and LILACS databases. In addition, we obtained 
4955 documents from other resources (figure 1). Our 
initial screening of titles and abstracts identified 230 
documents for assessment in full text, of which 45 were 
excluded due to they did not provide recommenda-
tions for clinical practice, 33 documents did not provide 
recommendations about COVID-19 testing, 27 addressed 
patients with other main pathologies or settings excluded 
to our review, and 16 were previous versions of included 
documents (online supplemental appendix 4). Finally, 47 
documents were included in evidence synthesis.33–79
Characteristics and quality of included guidance documents
Most of the included documents (n=28, 59%) were 
published de novo or have an updated version from 
May to September 2020 (table 1). Thirty- five docu-
ments were developed by institutions in America 
(n=15), Europe (n=10) and Asia (n=10). A consider-
able number of documents were developed by scien-
tific societies alone (n=21, 44%), while nine were 
produced by global/international health institutions, 
such as WHO and local/regional CDCs (19%), and 16 
remaining documents were developed by government 
agencies and Ministries of Health (34%). Fourteen docu-
ments reported a methodology to their development, 
including a search of primary evidence and experts meet-
ings,35 36 43 44 46 52 57 58 63 67 68 71 74 77 while 12 of them added a 
specific method to develop the recommendations, mostly 
based on expert consensus.35 36 43 44 46 57 58 63 67 68 71 74 Five 
documents explicitly stated that they followed the existing 
WHO/CDC guidelines to produce their own recommen-
dations.34 37 49 56 65 Fifteen documents did not present the 
recommendation in a clear format, such as a bullet list or 
a table; instead, they present the recommended actions 
in paragraphs along with other epidemiological infor-
mation.36 40 45 47 49 53 60 64 65 72 73 75–78 In addition, only 19 
documents reported the assessment of conflict of interest 
among the members of the expert panel producing the 
recommendations.35 37 42 44–48 52 57 58 60 62–64 67 68 74 79 Five 
Figure 1 Flow diagram of document selection for the 
scoping review of guidance on SARS- CoV-2/COVID-19 
testing. Additional records identified through other sources: 
TRIP database=3876 records; members of the International 
Society of antimicrobial chemotherapy=89 records; 
Canadian Medical Association (CMA) infobase/Clinical 
Practice Guidelines (CPGs). Database (CPGs)=151 records; 
who resources=164 records; Fisterra=38 records; other 
sources=637 records.
4 Arevalo- Rodriguez I, et al. BMJ Open 2021;11:e043004. doi:10.1136/bmjopen-2020-043004
Open access 
documents providing only recommendations about 
selected settings, mostly about deisolation.38 39 57 59 66
Regarding the quality of included documents, we found 
that the domains with the highest scores were ‘Scope 
and purpose’ (Median=50%; IQR=32–61) and ‘Clarity of 
presentation’ (Median=49%; IQR=33–67) (online supple-
mental appendix 5). Domains with the lowest scores 
were ‘Editorial independence’ (Median=4%; IQR=0–43) 
and ‘Applicability’ (Median=6%; IQR=0–21). Only six 
documents obtained at least 50% score for the ‘Rigour 
of development’ domain.35 36 44 46 63 67 Twelve documents 
obtained at least 50% scores for at least three AGREE- II 
domains.35–37 44 46 49 57 58 63 64 67 71 (online supplemental 
appendix 5).
Characteristics of the recommendations
We included 47 documents providing 327 recommenda-
tions about the diagnosis of COVID-19 cases (table 1). 
One hundred and fifty- seven recommendations were 
focused on the diagnosis of suspected cases (48%), 
while 39 sentences addressed deisolation measures of 
confirmed cases (11%). Forty- eight recommendations 
were against the use of a test in a specific setting (14%). 
The strength of recommendations was reported in 62 
statements (strong 33; weak 29).
The test most frequently recommended was the reverse 
transcription- PCR (RT- PCR) assays (87 recommenda-
tions), followed by chest CT (38 recommendations), and 
chest ultrasounds (22 recommendations). The test was 
not described or was no clearly reported in 48 recom-
mendations (ie, ‘COVID-19 testing’, ‘laboratory testing’). 
In addition, 79 recommendations reported tests for the 
investigation of competitive diagnoses, monitoring of 
disease and assessment of severity, such as blood counts, 
biomarkers, cultures and kidney and liver functions, 
among others.
An overview of the recommendations collated according 
to their role and application is presented as follow. Full 
text of all recommendations and areas of agreement with 
supporting documents can be consulted in online supple-
mental appendix 6.
Recommendations about incubation period (screening of 
asymptomatic and monitoring of contacts)
We identified 14 recommendations about the screening 
of asymptomatic patients and monitoring the contacts 
of confirmed cases, provided by four global health 
agencies,58 63 71 78 five scientific societies,35 42–44 70 78 and 
one government agency.37 RT- PCR assays were recom-
mended for testing of suspected cases, including those 
asymptomatic individuals in close contact with confirmed 
COVID-19 patients.37 44 58 One document developed by a 
scientific society recommends against the use of RT- PCR 
in asymptomatic patients with a low probability of being 
infected.44 Two documents recently published by global 
health agencies suggest the use of COVID-19 rapid 
antigen tests in cases of known exposure, even if individ-
uals are asymptomatic.71 78 In addition, two documents do 
not recommend the use of imaging (unclear which test) 
for the assessment of asymptomatic individuals.43 63 We 
identified three areas of agreement among developers, 
supported by two documents with Domain 3/AGREE II 
tool score ≥50%,44 63 regarding the role of RT- PCR assays 
and antigen- based tests (in favour) and chest imaging 
(against) in this setting (table 2).
Recommendations about symptomatic illness: screening 
symptomatic cases
We identified seven recommendations about case finding 
of symptomatic patients derived from six documents, 
including one global health agency,58 71 four scientific 
societies35 44 60 62 and one government agency.69 Recom-
mended test for the initial assessment of symptomatic 
Table 1 Characteristics of the documents included in the 
scoping review of guidance on SARS- CoV-2/COVID-19 
testing




March 2020 or earlier 11
April to May 2020 18
June to July 2020 7








Developer Global health agencies 
(ie, WHO and CDCs)
9
Government agencies 






























CDC, Centers for Disease Control and Prevention.
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Table 2 Testing of SARS- CoV-2/COVID-19: areas of consensus by developers












RT- PCR as the recommended test for investigation 
of asymptomatic and close contact
59 45a 38
Imaging is not routinely indicated as a screening test 
for COVID-19 in asymptomatic individuals
64* 44
COVID-19 rapid antigen tests as alternative tests 








Use of SARS- CoV-2 NAAT tests (including RT- PCR) 
as the recommended test for these cases
59, 72 45*, 36a
Chest CT should not be performed as a screening 
test in patients for possible COVID-19
61, 63
Diagnosis Use of RT- PCR as the recommended test for these 
cases
56, 59, 73 5, 36 *, 38, 
43, 45*, 52, 
55, 71, 78, 
65, 76
37*, 41, 50, 
51, 53, 54, 
57, 69, 66, 
75, 77, 74
General examination: including (but not limited to): 
physical examinatio, blood gas analysis/oxygen 
saturation, liver and kidney functions, complete 
blood count, among others
52, 55, 78, 
65
37*, 50, 54, 
57
Use of antibody- based (serological) tests for the 
diagnosis of acute COVID-19 is not recommended
59, 73, 62 71, 68*, 
36*
37*, 51, 54, 
66, 69, 75, 
70, 74
Repeat RT- PCR testing in cases where a patient with 
high suspicious of infection have an initial negative 
or undetermined results
73 36*, 45*, 
55, 61
38, 75
Specimen collection: respiratory tract samples, 
especially nasopharyngeal samples





38, 41, 42, 
50, 54, 57, 
74, 75
Restricted use of bronchoscopy for collection of 
specimens
36*, 46, 47, 




Collection of blood cultures for assessment of other 
agents causing pneumonia or sepsis
59 55, 36*, 43, 
78
37*, 50, 51, 
54, 70
Assessment of alternative respiratory infections, 
depending of local epidemiology
59, 73 35, 36, 43, 
65, 78
42, 50, 51, 
54, 74
Does not rule out COVID-19 in patients having 
positive findings for other pathogens and vice versa
59, 73 74, 51
Staging/grading 
severity
Use of chest CT and/or chest X- rays for hospital 
admission, diagnosis of pneumonia and related 
complications indicative of severity (such as acute 
respiratory distress syndrome (ARDS), pulmonary 
embolism)
64*, † 36*, 43, 44, 
55, 57, 60, 
61, 63
37*, 50
Monitoring Chest CT is recommended as follow- up test in cases 
of clinical deterioration and to detect complications
64*, † 36*, 60 50, 66
Limited role of chest X- rays, especially for daily use 
in stable patients
44, 63, 61
Monitoring of hospitalised patients with additional 
tests, including (but not limited to) vital signs 
measurement, oxygenation levels, acid- base balance 
assessment, D- dimer levels and ECG, among others.
43, 46, 55
Convalescence De- isolation/ 
discharge
Absence of clinical symptoms in the last 24–72 hours 
as a criteria for discharging patients from isolation
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individuals include the RT- PCR assays, rapid antigen tests 
and SARS- CoV-2 NAAT in general; this advice is supported 
by four documents, two of them with domain 3/AGREE II 
tool score ≥50%.35 44 58 71 Two documents developed by 
scientific societies do not recommend the use of Chest CT 
in the routinely screening of these patients60 62 (table 2).
Recommendations about symptomatic illness: diagnosis
We identified 157 recommendations about ruling in/
ruling out COVID-19 provided by 42 documents included 
in this scoping review. RT- PCR assays was the index test 
more recommended for the diagnosis of SARS- CoV-2 
infection (56 recommendations), supported by three 
documents with Domain 3/AGREE II tool score ≥50 %, 
among others.35 36 44 One document clarifies that a single 
positive PCR result is proof of infection, and there is no 
need for a second test in these cases.73 Twenty- one recom-
mendations about RT- PCR assays addressing technical 
issues, including the sampling specimen and the posi-
tivity criteria (ie, target genes). Seven documents recom-
mend a second RT- PCR assessment when there are high 
suspicious of infection and initial negative results, two 
of these documents with domain 3/AGREE II tool score 
≥50%.35 37 44 54 60 72 74 Sampling specimen more recom-
mended involving respiratory tract samples, especially 
nasopharyngeal samples.34 35 37 40 41 44 46 49 53 55 56 58 69 70 72–74 77 78
Fourteen documents recommend against the use 
of serological tests for the assessment of acute infec-
tion,36 50 53 58 65 67–70 72–74 reserving their role for late 
cases.35 61 This recommendation is supported by three 
documents with domain 3/AGREE II tool score ≥50 %, 
among others.35 36 67 Support about the use of chest CT 
in this setting is unclear, with five documents supporting 
their use in selected cases, for example, lack of availability 
of molecular tests,33 41 47 51 62 65 while other two documents 
clearly do not recommend their use.49 54 In addition, 
eight documents suggest a restricted use of bronchoscopy 
(two of them with domain 3/AGREE II tool score ≥50 %), 
for example, for intubated patients.35 45 46 48 51 54 64 79
We found a considerable number of recommenda-
tions which failed in the reporting of the index test (ie, 
COVID-19 tests, chest imaging), and then there was no 
possible their classification in these analyses. Other areas 
of consensus are shown also in table 2.
Recommendations about symptomatic illness: competitive 
diagnosis
We identified 31 recommendations about the assessment 
of competitive diagnosis derived from 17 documents, 
mainly scientific societies.34–36 41 42 45 48–50 53 54 58 64 69 72 73 77 
Twenty- eight recommendations state the need for explo-
ration of alternative respiratory infections, such as influ-
enza, tuberculosis or bacterial pneumonia, supported 
by two documents with domain 3/AGREE II tool score 
≥50 %, among others.35 36 Areas of agreement include 
the collection of blood cultures for assessment of other 
agents causing respiratory infections,34–36 42 49 50 53 58 69 77 
the assessment of other potential aetiologies depending 
on local epidemiology, such as Streptococcus pneumo-
niae, Haemophilus influenzae and Mycobacterium tuber-
culosis,34 41 42 49 50 53 58 64 72 73 77 as well as the follow- up 
of COVID-19 diagnosis even if other infections are 
confirmed (table 2).50 58 72 73
Recommendations about symptomatic illness: staging/
grading severity
We identified 36 recommendations about staging/
grading the severity of COVID-19 patients provided by 
12 documents (three of them with domain-3/AGREE- II 
tool score ≥50%), most of them produced by scientific 
societies.35 36 41–43 49 54 56 59 60 62 63 Twenty- two recommen-
dations addressed the role of imaging tests, including 
chest CT in the evaluation of disease extent (ie, signs 
of pulmonary oedema, acute respiratory distress 
syndrome (ARDS), pleural effusions, need for ventila-
tion)36 42 49 54 56 59 60 62 and lung X- rays for the identification 
of lung lesions.35 36 42 43 62 One document suggest the use 
of Chest X- rays as an alternative in resource- constrained 
scenarios, based on information current in April 2020.43 
Three documents, including one developed by a global 
health agency, recommend the use of chest imaging 
(unclear tests) in addition to other clinical and laboratory 
tests (table 2).35 43 63 One additional document recom-
mend against the request of additional examinations in 
the absence of vital signs altered or risk factors.35
Recommendations about symptomatic illness: monitoring and 
therapeutic management
We identified 28 recommendations about moni-
toring/follow- up of patients derived from 12 










The role of serological tests in surveillance studies 40, 73 36* 69, 50
*Document with a score of 50% or more for the ‘Rigour of development’ domain.
†Index test included in the ‘chest imaging’ category. Two or more expert panels supported the areas of consensus detailed above. Due to 
information on COVID-19, virus is rapidly evolving, some of these actions would be modified when new evidence become available.
NAAT, nucleic acid amplification test; RT- PCR, reverse transcription- PCR.
Table 2 Continued
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documents.35 42 43 45 49 54 59 60 62–65 Chest CT imaging is 
recommended as a follow- up test by five documents, 
three of them with Domain-3/AGREE- II Tool score 
≥50%.35 49 59 65 An additional three documents are against 
the use of daily chest x- ray in stable patients,43 62 restricting 
its use to severe cases.60 One document provides five 
recommendations about the use of RT- PCR in the viro-
logical monitoring of COVID-19 patients.42 Other index 
tests involved in the monitoring of patients include vital 
signs measurement, oxygenation levels, acid- base balance 
assessment, D- dimer levels and ECG, according to three 
documents developed by scientific societies.42 45 54 Areas 
of agreement supported by two or more documents are 
shown in table 2.
Recommendations about convalescence: deisolation/
discharge
We identified 39 recommendations about de- isolation/
discharge from hospitalisation, derived from 18 docu-
ments: 4 developed by global/international health 
agencies,38 55 58 63 6 by scientific societies34 35 42 43 51 70 and 
the remaining by government agencies.37 40 41 56 57 66 73 74 
Absence of clinical symptoms in the last 24–72 hours (ie, 
fever and/or respiratory symptoms) are a common issue 
for most of the documents addressing hospital discharge/
deisolation.34 35 38 40 51 55 56 58 66 70 74 RT- PCR negative results 
(including double negative results) are recommended 
by six documents, most of them developed before May 
2020,37 38 40 42 51 55 while four documents, including one 
developed by a global health agency, stated that this 
test is not required for all cases.35 58 73 74 Duration of the 
quarantine is highly heterogeneous and based on several 
criteria; most common recommendations for asymptom-
atic or mild patients ranged from 1058 74 to 14 days.35 57 70 73
Other recommendations
We identified 15 recommendations about other issues, 
provided by ten documents, most of them developed by 
global health and government agencies.35 37 39 44 49 68 71 72 74 78
Those recommendations addressed the unclear role 
of antigen- based tests in other scenarios outside diag-
nosis of symptomatic patients,39 71 74 78 and the role of 
serological tests in surveillance studies,35 39 49 68 72 among 
others. Full information is provided in online supple-
mental appendix 4.
DISCUSSION
In this scoping review of recommendations about 
COVID-19 testing, we identified 47 guidance documents 
containing 327 recommendations for different stages of 
the disease, including SARS- Cov-2 detection, assessment 
of another competitive diagnosis, staging and moni-
toring of symptomatic cases and deisolation discharge 
of hospitalised patients. Our review included documents 
produced by global healthcare organisations (ie, WHO, 
CDCs), scientific societies and government agencies (such 
as Ministries of Health) from several countries around 
the world. Although we included the last version of all 
documents to warrant the currency of the recommenda-
tions, we still found documents developed earlier at the 
beginning of the pandemic (before March 2020), which 
could have an impact in the content of the recommen-
dations provided by these groups. The recommendations 
are current at the time our searches were conducted. 
Future updates may change the recommendations if new 
evidence about COVID-19 testing emerges. Despite these 
limitations, it was possible to map the role of well- known 
tests such as RT- PCR assays, imaging and serological tests 
in the comprehensive assessment of COVID-19. We found 
a predominant role for the NAAT (ie, RT- PCR test) in 
several stages of the disease. Besides, we identified the role 
of imaging tests to grade the severity of the disease. As a 
summary of the numerous recommendations provided by 
the different developers, we identified areas of consensus 
for testing actions in different disease stages. These areas 
included the use of RT- PCR for SARS- Cov-2 detection, 
the limited role of bronchoscopy, and the use of chest CT 
and chest x- rays for grading severity, among other recom-
mended actions. Due to information on COVID-19 virus 
is rapidly evolving, some of these actions would be modi-
fied when new evidence become available.
The quality of the development of these documents 
was assessed by a standardised and well developed tool 
(AGREE- II tool), which evaluate key elements to warrant 
the transparency, adequacy and applicability of all recom-
mended actions in the clinical setting. Unfortunately, 
we found several constraints during the development of 
these recommendations reflected in the AGREE- II scores. 
Most of the documents did not report the steps taken to 
develop either the full document or the recommenda-
tions; for those reporting a methodology, only a small 
fraction (6 out of 14 documents) obtained a score of at 
least 50% in the AGREE- II/domain 3 (‘Rigour of devel-
opment’), all of them developed after April 2020. Addi-
tional key issues addressed by the AGREE- II tool, such as 
the Editorial independence (to confirm that the formula-
tion of recommendations was not biased with competing 
interests), also received lowest scores.
This scoping review was based on a comprehensive 
search and assessment of the literature about COVID-19 
testing. Despite that some documents developed their 
recommendations with unclear methods, we were able 
to identify several areas of agreement for COVID-19 
testing among all included studies; most of these areas 
are supported by documents whose reported a systematic 
search of the literature, a fair evaluation of the strengths 
and limitation of the evidence, and a clear methodology 
to reach consensus around the recommended actions, 
according to the AGREE- II tool. We also performed a 
regular update of searches and updated our findings to 
reflect the current recommended practice in this field. 
However, our review has some limitations. We mostly relied 
on the search of guideline repositories, documents linked 
to scientific societies and publications in indexed journals 
to inform this scoping review. We considered that this 
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strategy would identify documents with greater support 
given by experts and professional societies. Although we 
conducted a specific search of guidance developed by 
experts based on the 30 countries more affected by the 
pandemic, it is possible that some such guidelines could 
be missing. Official agencies were probably not prepared 
to release their advice to governments in a sensitive polit-
ical atmosphere. In addition, some guidance documents 
developed by other countries not currently included in 
our scoping review were excluded, due to they did not 
provide recommendations for the diagnosis of COVID-
19, focus their efforts in recommendations about treat-
ments (see figure 1 for these exclusions).
Our scoping review also is limited to the assessment 
of adult healthier population, excluding the evaluation 
of special populations, including people in high- risk of 
having COVID-19. While a broader scope would have been 
of greater interest for readers, the multiplicity of sources 
and the particularities of recommendations are important 
constraints in order to warrant the comprehensiveness of a 
systematic review. We decided to be cautious in this issue, 
and rather prefer to reflect a comprehensive and complete 
overview of testing recommendations to be applied to the 
general population.
When we used the AGREE- II tool to assess the quality of 
all included documents, we did not expect full compliance 
in all domains, but we did consider that a minimum of key 
characteristics would be fulfilled in documents providing 
formal recommendations for testing.80 Unfortunately, we 
noted many deficiencies, a feature that was disturbing, 
given that the severity of the pandemic demanded the 
highest level of rigour despite the pressure of time. The 
lack of reporting concerning critical issues like conflict 
of interest, judgements about evidence quality, and the 
methods to formulate recommendations, reduce the confi-
dence stakeholders have when implementing the recom-
mended action in daily practice. Development of formal 
clinical practice guidelines is a time- consuming task but 
with prioritisation and resource allocation quality need not 
be compromised. Even if the reason for these shortcomings 
was the need to provide quick guidance in response to the 
COVID-19 emergency, readers should be aware that there 
are quality standards expected in rapid guidelines.81
Timely and accurate testing is a key element for the 
control of COVID-19.82 83 This, to our knowledge, is the 
first scoping review focusing on recommendations exclu-
sively for COVID-19 testing, with information current 
until 21 September 2020. However, as new evidence about 
COVID-19 testing emerges, the recommended actions 
would need updating and a living systematic review could 
offer the best approach for addressing this issue timely.
Author affiliations
1Clinical Biostatistics Unit, Hospital Universitario Ramón y Cajal, IRYCIS, CIBER of 
Epidemiology and Public Health, Madrid, Spain
2Department of Internal Medicine, Faculty of Medicine, Universidad de La Frontera, 
Temuco, Chile
3Institute of Social and Preventive Medicine (ISPM), University of Bern, Switzerland, 
Bern, Switzerland
4Instituto de Efectividad Clínica y Sanitaria (IECS- CONICET), Buenos Aires, Argentina
5Clinical Biostatistics Unit, Hospital Universitario Ramón y Cajal, CIBER of 
Epidemiology and Public Health, Madrid, Spain
6Centro de investigación en Salud Pública y Epidemiología Clínica (CISPEC). 
Facultad de Ciencias de la Salud “Eugenio Espejo”, Universidad UTE, Quito, Ecuador
7Department of Microbiology, Ramón y Cajal University Hospital, Ramón y Cajal 
Health Research Institute (IRYCIS), Madrid, Spain
8Department of Microbiology, Ramón y Cajal University Hospital. Ramón y Cajal 
Health Research Institute (IRYCIS), CIBER of Epidemiology and Public Health 
(CIBERESP), Madrid, Spain
9Infectious Diseases Department, National Referral Centre for Tropical Diseases, 
Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain
10Department of Preventive Medicine and Public Health, Faculty of Medicine, 
University of Granada, CIBER of Epidemiology and Public Health, Granada, Spain
11Institute of Applied Health Research, University of Birmingham, Birmingham, UK
Acknowledgements The authors thanks Andrea Correa Perez for her support 
in the AGREE- II assessment of included documents. Ingrid Arevalo- Rodriguez is 
funded by the Instituto de Salud Carlos III through the 'Acción Estrategica en Salud 
2013-2016 / Contratos Sara Borrell convocatoria 2017/CD17/00219' (Cofunded by 
European Social Fund 2014-2020, 'Investing in your future'). KSK is distinguished 
investigator at University of Granada funded by the Beatriz Galindo (senior modality) 
programme of the Spanish Ministry of Education.
Contributors IA- R and JZ conceived the study. IA- R, JZ, PS, DB- G, AC, DS- R, 
JAP- M and JZ designed the study. IA- R, PS, DB- G and PZ- A screened titles and 
abstracts for inclusion. IA- R, PS, DB- G, AC, AM, PZ- A, DS- R, RdC and JAP- M 
extracted and analyzed data. AC, RdC, JCG- M, KSK and JAP- M helped interpret the 
findings from a clinical viewpoint. IA- R, PS, KSK and JZ wrote the first draft, which 
all authors revised for critical content. All authors approved the final manuscript. 
IA- R and JZ are the guarantors. The corresponding author attests that all listed 
authors meet authorship criteria and that no others meeting the criteria have been 
omitted.
Funding The authors have not declared a specific grant for this research from any 
funding agency in the public, commercial or not- for- profit sectors.
Competing interests All authors have completed the ICMJE uniform disclosure 
form at www. icmje. org/ coi_ disclosure. pdf and declare: no support from any 
organisation for the submitted work; KSK has been paid for developing and 
delivering educational presentations for Ferring Pharmaceuticals and Olympus 
company; KSK has been an editor of medical Journals including BJOG, EBM- 
BMJ, BMC Med Edu; no other relationships or activities that could appear to have 
influenced the submitted work.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement Data are available on reasonable request. The study 
protocol is available online at https:// osf. io/ yqv54/. Most included studies are 
publicly available. Additional data are available on reasonable request.
Supplemental material This content has been supplied by the author(s). It 
has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have 
been peer- reviewed. Any opinions or recommendations discussed are solely 
those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability 
and responsibility arising from any reliance placed on the content. Where the 
content includes any translated material, BMJ does not warrant the accuracy and 
reliability of the translations (including but not limited to local regulations, clinical 
guidelines, terminology, drug names and drug dosages), and is not responsible 
for any error and/or omissions arising from translation and adaptation or 
otherwise.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non- commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
ORCID iDs
Ingrid Arevalo- Rodriguez http:// orcid. org/ 0000- 0002- 7326- 4504
Alfonso Muriel http:// orcid. org/ 0000- 0002- 4805- 4011
Javier Zamora http:// orcid. org/ 0000- 0003- 4901- 588X
9Arevalo- Rodriguez I, et al. BMJ Open 2021;11:e043004. doi:10.1136/bmjopen-2020-043004
Open access
REFERENCES
 1 World Health Organization. Coronavirus disease 2019 (COVID-19): 
situation report – 102. Switzerland: Geneve, 2020.
 2 Meo SA, Alhowikan AM, Al- Khlaiwi T, et al. Novel coronavirus 2019- 
nCoV: prevalence, biological and clinical characteristics comparison 
with SARS- CoV and MERS- CoV. Eur Rev Med Pharmacol Sci 
2020;24:2012–9.
 3 Legido- Quigley H, Asgari N, Teo YY. Are high- performing health 
systems resilient against the COVID-19 epidemic? Lancet 
2020;395:848–50.
 4 Gostin LO. Public health emergency preparedness: globalizing risk, 
localizing threats. JAMA 2018;320:1743–4.
 5 Lin C, Ye R, Xia YL. A meta- analysis to evaluate the effectiveness of 
real- time PCR for diagnosing novel coronavirus infections. Genet Mol 
Res 2015;14:15634–41.
 6 Sharfstein JM, Becker SJ, Mello MM. Diagnostic testing for the novel 
coronavirus. JAMA 2020;323:1437–8.
 7 Cheng H- Y, Jian S- W, Liu D- P, et al. Contact tracing assessment 
of COVID-19 transmission dynamics in Taiwan and risk at different 
exposure periods before and after symptom onset. JAMA Intern Med 
2020;180:1156–63.
 8 Peto J. Covid-19 mass testing facilities could end the epidemic 
rapidly. BMJ 2020;368:m1163.
 9 Rosenbaum L. Facing covid-19 in Italy — ethics, logistics, and 
therapeutics on the epidemic’s front line. N Engl J Med Overseas Ed 
2020;382:1873–5.
 10 Kwon KT, Ko JH, Shin H, et al. Drive- through screening center for 
COVID-19: a safe and efficient screening system against massive 
community outbreak. J Korean Med Sci 2020;35:e123.
 11 CDC, United States Centers for Disease Control and Prevention. 
Evaluating and testing persons for coronavirus disease 2019 
(COVID-19), 2020. Available: https://www. cdc. gov/ coronavirus/ 2019- 
ncov/ hcp/ clinical- criteria. html? CDC_ AA_ refVal= https% 3A% 2F% 
2Fwww. cdc. gov% 2Fcoronavirus% 2F2019- ncov% 2Fclinical- criteria. 
html
 12 World Health Organization. Infection prevention and control guidance 
for long- term care facilities in the context of COVID-19. March 21 
2020 ED. 2020. Geneve, Switzerland: World Health Organization.
 13 World Health Organization. Laboratory testing strategy 
recommendations for COVID-19: interim guidance. Switzerland: 
Geneve, 2020.
 14 Wynants L, Van Calster B, Collins GS, et al. Prediction models for 
diagnosis and prognosis of covid-19 infection: systematic review and 
critical appraisal. BMJ 2020;369:m1328. doi:10.1136/bmj.m1328
 15 Lv M, Wang M, Yang N, et al. Chest computed tomography for the 
diagnosis of patients with coronavirus disease 2019 (COVID-19): a 
rapid review and meta- analysis. Ann Transl Med 2020;8:622.
 16 Arevalo- Rodriguez I, Buitrago- Garcia D, Simancas- Racines D, et al. 
False- negative results of initial RT- PCR assays for COVID-19: a 
systematic review. PLoS One 2020;15:e0242958.
 17 European Commission’s COVID-19 advisory panel. EU 
recommendations for testing strategies. Brussels: European Union, 
2020.
 18 Government of Canada. Infection prevention and control for 
coronavirus disease (COVID-19): interim guidance for acute 
healthcare settings. Canada: Public Health Agency of Canada, 2020.
 19 World Health Organization. Laboratory testing for coronavirus disease 
(COVID-19) in suspected human cases. interim guidance. Geneve, 
Switzerland: World Health Organization, 2020.
 20 World Health Organization. Clinical management of severe acute 
respiratory infection (SARI) when COVID-19 disease is suspected. 
v1.2. Geneve, Switzerland: World Health Organization, 2020.
 21 Dagens A, Sigfrid L, Cai E, et al. Scope, quality, and inclusivity of 
clinical guidelines produced early in the covid-19 pandemic: rapid 
review. BMJ 2020;369:m1936.
 22 Li Y, Li J, Zhong D, et al. Clinical practice guidelines and experts' 
consensuses of traditional Chinese herbal medicine for novel 
coronavirus (COVID-19): protocol of a systematic review. Syst Rev 
2020;9:170.
 23 Luo W- Y, Sun J- W, Zhang W- L, et al. Management in the paediatric 
wards facing novel coronavirus infection: a rapid review of guidelines 
and consensuses. BMJ Open 2020;10:e039897.
 24 SGK O, Lim WY, Ong J. Anesthesia guidelines for COVID-19 patients 
- A narrative review and appraisal. Korean J Anesthesiol 2020 
(published Online First: 2020/07/17).
 25 Vargas- Peirano M, Navarrete P, Díaz T, et al. Care of 
Ophthalmological patients during the COVID-19 pandemic: a rapid 
scoping review. Medwave 2020;20:e7902.
 26 World Health Organization. Coronavirus disease (COVID-19). 
Situation report – 153. Geneve, Switzerland: World Health 
Organization, 2020.
 27 Brouwers MC, Kho ME, Browman GP, et al. Agree II: advancing 
Guideline development, reporting and evaluation in health care. 
CMAJ 2010;182:E839–42.
 28 Brouwers MC, Kho ME, Browman GP, et al. Agree II: advancing 
Guideline development, reporting and evaluation in health care. J 
Clin Epidemiol 2010;63:1308–11.
 29 Browman GP. Clinical practice guidelines and healthcare decisions: 
credibility gaps and unfulfilled promises? Nat Clin Pract Oncol 
2005;2:480–1.
 30 Kahn SE, Astles JR, Lo SF, et al. The agree II instrument is helpful 
for creation of national Academy of clinical biochemistry laboratory 
medicine practice guidelines. Clin Chem 2013;59:446–7.
 31 Cheng MP, Papenburg J, Desjardins M, et al. Diagnostic testing 
for severe acute respiratory syndrome- related coronavirus 2: a 
narrative review. Ann Intern Med 2020;172:726–34. doi:10.7326/
M20-1301
 32 Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping 
reviews (PRISMA- ScR): checklist and explanation. Ann Intern Med 
2018;169:467–73.
 33 American Collegue of Radiology. ACR recommendations for the use 
of chest radiography and computed tomography (CT) for suspected 
COVID-19 infection. Virginia: American Collegue of Radiology, 2020.
 34 Comité de Infecciones Emergentes. Recomendaciones Manejo 
Clínico de Infección Respiratoria POR Nuevo coronavirus 2019 (2019 
n- COV). Chile: Sociedad Chilena de Infectología, 2020.
 35 Asociación Colombiana de Infectología. Consenso Colombiano de 
Atención, Diagnóstico Y Manejo de la Infección POR SARS- CoV-2/ 
COVID-19 en establecimientos de atención de la salud. Infectio 
2020;24:1–163.
 36 Secretaria de Ciência Tecnologia Inovação e Insumos Estratégicos 
em Saúde (SCTIE). Diretrizes para Diagnóstico E Tratamento dA 
COVID-19. Brasilia, Brazil: Ministério da saúde, 2020.
 37 Hong KH, LeeKim SW, Soo T. Guidelines for laboratory diagnosis of 
coronavirus disease 2019 (COVID-19) in Korea. Annals of Laboratory 
Medice 2020;40:351–60.
 38 European Centre for Disease Prevention and control. Guidance 
for discharge and ending isolation in the context of widespread 
community transmission of COVID-19, 8 April 2020. Stockholm: 
ECDC, 2020.
 39 World Health Organization. Advice on the use of point- of- care 
immunodiagnostic tests for COVID-19. Geneve, Switzerland: World 
Health Organization, 2020.
 40 (Released by National Health Commission & National Administration 
of Traditional Chinese Medicine on March 3, 2020). Diagnosis and 
treatment protocol for novel coronavirus pneumonia (trial version 7). 
Chin Med J 2020;133:1087–95.
 41 Ministerio de Sanidad. Manejo clínico del COVID-19: atención 
hospitalaria. Madrid, España: Gobierno de España, 2020.
 42 Flisiak R, Horban A, Jaroszewicz J. Recommendations of 
management in SARS- CoV-2 infection of the Polish association 
of epidemiologists and Infectiologists. Pol Arch Intern Med 
2020;130:358–67.
 43 Rubin GD, Ryerson CJ, Haramati LB, et al. The role of chest 
imaging in patient management during the COVID-19 pandemic: 
a multinational consensus statement from the Fleischner Society. 
Radiology 2020;296:172–80.
 44 Hanson KE, Caliendo AM, Arias CA. Infectious diseases Society of 
America guidelines on the diagnosis of COVID-19. Arlington, VA: 
Infectious Diseases Society of America, 2020.
 45 Cordovilla R, Álvarez S, Llanos L, et al. Recomendaciones de 
consenso SEPAR Y AEER sobre El uso de la broncoscopia Y 
La toma de muestras de la vía respiratoria en pacientes Con 
sospecha O Con infección confirmada POR COVID-19. Archivos de 
Bronconeumología 2020;56:19–26.
 46 Wahidi MM, Shojaee S, Lamb CR, et al. The use of bronchoscopy 
during the coronavirus disease 2019 pandemic: CHEST/AABIP 
guideline and expert panel report. Chest 2020;158:1268-1281.
 47 Yang Q, Liu Q, Xu H, et al. Imaging of coronavirus disease 2019: a 
Chinese expert consensus statement. Eur J Radiol 2020;127:109008.
 48 Luo F, Darwiche K, Singh S, et al. Performing bronchoscopy in times 
of the COVID-19 pandemic: practice statement from an international 
expert panel. Respiration 2020;99:417–22.
 49 Ministry of Health. Temporary methodical recommendations 
prevention, diagnostics and treatment of new coronaviral infection 
(COVID-19)]. V8.0. Russia: Russian Federation, 2020.
 50 Ministry of Health and Family Welfare. Clinical management protocol: 
COVID-19. version 5 ED. New Delhi, India: Government of India, 
Directorate General of Health Services (EMR Division), 2020.
 51 Comité de Trabajo COVID-19. Lineamientos de Manejo hospitalario 
del paciente con COVID-19. Peru: Sociedad Peruana de Neumología, 
2020.
10 Arevalo- Rodriguez I, et al. BMJ Open 2021;11:e043004. doi:10.1136/bmjopen-2020-043004
Open access 
 52 IETSI/EsSalud. Recomendaciones de manejo clínico para Los 
casos de COVID-19. Peru: INSTITUTO DE EVALUACIÓN DE 
TECNOLOGÍAS EN SALUD E INVESTIGACIÓN, 2020.
 53 STAKOB. Permanent Working group of competence and treatment 
centers for diseases caused by highly pathogenic pathogens at 
the Robert Koch Institute. Germany: STAKOB office- Robert Koch 
Institute, 2020.
 54 Pakistan Chest Society (PCS) Guidelines Working Group. Guidelines 
on management of patients with COVID-19. Second edition. 
Pakistan: Pakistan Chest Society, 2020.
 55 Ministry of Health. Coronavirus disease COVID-19 guidelines. Version 
1.3. Saudi Arabia: Saudi Center for Disease Control and Prevention, 
2020.
 56 Disease Control Division. National guidelines on clinical management 
of coronavirus disease 2019 (COVID-19). Version 7.0 ed. Bangladesh: 
Ministry of Health & Family Welfare, Government of the People’s 
Republic of Bangladesh, 2020.
 57 Ministry of Health. Consenso interino multidisciplinario informado 
en La evidencia sobre El tratamiento de COVID19. Ecuador: 
Government of Ecuador, 2020.
 58 World Health Organization. Clinical management of COVID-19. 
Geneve, Switzerland: World Health Organization, 2020.
 59 SdI T. Imagerie thoracique au déconfinement - Positionnement de la 
SIT. France: SIT - Société d'Imagerie Thoracique, 2020.
 60 Revel M- P, Parkar AP, Prosch H, et al. COVID-19 patients and 
the radiology department - advice from the European Society of 
Radiology (ESR) and the European Society of Thoracic Imaging 
(ESTI). Eur Radiol 2020;30:4903–9.
 61 Prevention CfDCa. Interim guidelines for COVID-19 antibody testing. 
Atlanta, USA: CDC- Centers for Disease Control and Prevention, 
2020.
 62 Dennie C, Hague C, Lim RS, et al. Canadian Society of thoracic 
Radiology/Canadian association of radiologists consensus statement 
regarding chest imaging in suspected and confirmed COVID-19. Can 
Assoc Radiol J 2020;71:846537120924606.
 63 World Health Organization. Use of chest imaging in COVID-19: a 
rapid advice guide. Geneve, Switzerland: World Health Organization, 
2020.
 64 Nielsen Jeschke K, Bonnesen B, Hansen EF, et al. Guideline for the 
management of COVID-19 patients during hospital admission in a 
non- intensive care setting. Eur Clin Respir J 2020;7:1761677.
 65 Ministry of Health. SARS- CoV-2 infection General information, 
epidemiology and diagnosis. Ankara, Turkey: Ministry of Health, 
Turkey, 2020.
 66 High Council of Public Health. Clinical criteria for leaving isolation of 
patients having been infected with SARS- CoV-2. France: Directorate 
General of Health (DGS), 2020.
 67 Hanson KE, Caliendo AM, Arias CA. Infectious diseases Society of 
America guidelines on the diagnosis of COVID-19: serologic testing. 
Arlington, VA: Infectious Diseases Society of America, 2020.
 68 COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 
(COVID-19) treatment guidelines. USA: National Institutes of Health, 
2020.
 69 Public Health Agency of Canada. Clinical management of patients 
with COVID-19: second interim guidance. Canada: Agence de la 
Sante publique Du Canada, 2020.
 70 EBM Guidelines. Coronavirus infections. September 4 2020 ed. 2020. 
Finland: EBM Guidelines.
 71 World Health Organization. Antigen- detection in the diagnosis of 
SARS- CoV-2 infection using rapid immunoassays: interim guidance. 
Geneve, Switzerland: World Health Organization, 2020.
 72 World Health Organization. Diagnostic testing for SARS- CoV-2. 
interim guidance. Geneve, Switzerland: World Health Organization, 
2020.
 73 National Institute for Communicable Diseases (NICD). Guidelines for 
case- finding, diagnosis, and public health response in South Africa. in: 
centre for respiratory diseases and meningitis (CRDM) and outbreak 
response unit DoPHSaR, ed. V3 ed. Republic of South Africa: National 
Department of Health, Republic of South Africa, 2020.
 74 National Institute for Communicable Diseases Department. Clinical 
management of suspected or confirmed COVID-19 disease. in: 
department of health, ed. V5 ed. South Africa: Republic of South 
Africa, 2020.
 75 Associação Médica Brasileira. DIRETRIZES Amb: COVID – 19. Brazil: 
Associação Médica Brasileira, 2020.
 76 National Institute for Health and Environment. COVID-19 guideline. 
The Netherlands: Ministry of Health, wellbeing and sports, 2020.
 77 Cabrera- Rayo A C- MH, Sánchez- Echeverría JC. Recomendaciones 
de colegios, sociedades médicas Y grupos de trabajo mexicanos 
para El diagnóstico, tratamiento, prevención Y control del SARS- 
CoV-2 (COVID-19). Med Int Mex 2020;36:1–85.
 78 Centers for Disease Control and Prevention. Interim guidance for 
rapid antigen testing for SARS- CoV-2 using antigen tests. Atlanta, 
USA: CDC- Centers for Disease Control and Prevention, 2020.
 79 Yang H, Chen H, Gao B, et al. Expert panel consensus statement 
on the applications and precaution strategies of bronchoscopy in 
patients with COVID-19. Endosc Ultrasound 2020;9:211–9.
 80 Morgan RL, Florez I, Falavigna M, et al. Development of rapid 
guidelines: 3. GIN- McMaster Guideline development checklist 
extension for rapid recommendations. Health Res Policy Syst 
2018;16:63.
 81 Garritty CM, Norris SL, Moher D. Developing who rapid advice 
guidelines in the setting of a public health emergency. J Clin 
Epidemiol 2017;82:47–60.
 82 Sethuraman N, Jeremiah SS, Ryo A. Interpreting diagnostic tests for 
SARS- CoV-2. JAMA 2020;323:2249-2251.
 83 Watson J, Whiting PF, Brush JE. Interpreting a covid-19 test result. 
BMJ 2020;369:m1808.
